In 2014, “NephroCheck” was approved by the U.S. Food and Drug Administration for the detection of TIMP-2 and IGFBP-7 levels in urine to predict the likelihood of AKI in critically ill patients. The gene discussed is TIMP2; the disease is acute kidney injury.